Amyotrophic Lateral Sclerosis: a New Paradigm (ALSParadigm)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03073239|
Recruitment Status : Recruiting
First Posted : March 8, 2017
Last Update Posted : March 8, 2017
Amyotrophic Lateral Sclerosis (ALS) is a degenerative neuromuscular disease, progressing inexorably to respiratory failure, the by involvement of respiratory muscles, the commitment with most impact on the prognosis of ALS.
According to current knowledge, the clinical presentation of the disease is characterized by spinal or bulbar involvement, the latter being associated with a worse prognosis.
There are multiple factors described in the aetiology of ALS, as the successive damage the motor neuron, which can happen in high-impact athletes, or exposure to heavy metals. Genetic mutations are also described, being associated to a higher prevalence of ALS.
Data from retrospective studies with ALS populations reveal a prevalence of 4-8 cases per 100,000 persons. Research carried out in Trás-os-Montes e Alto Douro region (Northeast of Portugal) shows a high prevalence of ALS, with near 10 cases per 100,000 persons, with a recent increase in the bulbar involvement. The reasons for the high prevalence of ALS in this region are unknown.
|Condition or disease||Intervention/treatment|
|Amyotrophic Lateral Sclerosis||Other: study ALS patients|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Amyotrophic Lateral Sclerosis: a New Paradigm|
|Actual Study Start Date :||December 2016|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2018|
ALS patients group sent for respiratory evaluation
Other: study ALS patients
Characterization of epidemiological features and genetic.
- Finding environmental risk factor [ Time Frame: 2 years ]Apply epidemiogycal form to All ALS patients sentido to respiratory evaluation in 2 years.
- Regional prevalence [ Time Frame: 1 year ]Identify All cases ALS in regional area ( in north of Portugal)
- Finding a genetic marker [ Time Frame: 2 years ]Scan all ALS patients to eventually finding new ALS genes
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03073239
|Contact: Bebiana Conde, MDemail@example.com|
|Contact: Bebiana Conde, MD||00351259300500 ext 5291|
|Centro Hospitalar Tras-os-Montes e Alto Douro||Recruiting|
|Vila Real, Portugal, 5000|
|Contact: Bebiana Conde, MD 00351936305294 firstname.lastname@example.org|
|Contact: Bebiana Conde, MD 00351259300500 ext 5291 email@example.com|
|Principal Investigator:||Bebiana Conde, MD||Centro Hospitalar Tras-os-Montes e Alto Douro|